Your session is about to expire
← Back to Search
Neoadjuvant Cemiplimab for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer drug to see if it is effective at treating three different types of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 138 Patients • NCT03132636Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never smoked or have smoked less than 100 cigarettes in my lifetime.I haven't had encephalitis, meningitis, or uncontrolled seizures in the last year.I am willing to undergo a biopsy before starting cemiplimab treatment.I haven't had cancer treatment or radiation in the last 6 months.My lung cancer has EGFR, ALK, or ROS1 genetic changes.My surgery for metastatic disease is not intended to cure.I am fully active or restricted in physically strenuous activity but can do light work.I have another cancer, but it's either treated or not worsening.I haven't taken steroids or immunosuppressants in the last 7 days.I am considered fit for surgery to remove my tumor.I have had lung conditions treated with steroids but not due to infection.I have been diagnosed with NSCLC, HCC, or HNSCC.I have not had major surgery in the last 14 days.My organs and bone marrow are working well.I do not have an uncontrolled HIV, HBV, or HCV infection, nor an immunodeficiency.
- Group 1: Cohort B2
- Group 2: Cohort A3
- Group 3: Cohort B3
- Group 4: Cohort A1
- Group 5: Cohort A2
- Group 6: Cohort B
- Group 7: Cohort C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit for how many people can take part in this experiment?
"That is accurate. The trial was first posted on 7/23/2019 and was last edited on 11/24/2021. The study is searching for 88 patients across 1 locations."
What percentage of people experience negative side effects from cemiplimab?
"While cemiplimab has shown some efficacy in prior clinical trials, it has not yet been cleared for use. Therefore, it received a score of 2."
What are cemiplimab's most common indications?
"The cemiplimab medication can be used to treat alk gene mutation, malignant neoplasms, and to follow advance directives."
Are new participants able to join this research project?
"Correct, this clinical trial is still open and actively recruiting patients. The listing was first posted on 7/23/2019, with the most recent update taking place on 11/24/2021."
Share this study with friends
Copy Link
Messenger